

Table SI. Serum CXCL13 in control patients with various dermatological diseases

Diagnosis	Serum CXCL13 (pg/ml) Median (min–max)
Basal cell carcinoma (<i>n</i> =7)	94 (37–130)
Squamous cell carcinoma (<i>n</i> =4)	98 (87–165)
Melanoma (<i>n</i> =16)	77 (36–247)
Other malignancies (<i>n</i> =5)	189 (78–500)
Erysipelas (<i>n</i> =7)	102 (58–156)
Psoriasis vulgaris (<i>n</i> =15)	87 (60–137)
Other inflammatory dermatoses (<i>n</i> =4)	151 (44–419)
Herpes zoster (<i>n</i> =2)	96; 77
Autoimmunological disorders (<i>n</i> =4)	89 (77–292)
Peripheral vascular disease (<i>n</i> =6)	58.5 (38–95), 1 Pat: 335 (breast cancer)
Acne vulgaris (<i>n</i> =1)	64
Type I allergy (<i>n</i> =15)	54 (36–95)
Contact dermatitis (<i>n</i> =2)	81; 175
Atopic dermatitis (<i>n</i> =3)	73; 120; 244
Urticaria (<i>n</i> =5)	87 (52–143)
Pruritus (<i>n</i> =1)	62